HC Wainwright Has Lowered Expectations for Dyne Therapeutics (NASDAQ:DYN) Stock Price

Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by stock analysts at HC Wainwright from $55.00 to $46.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 237.99% from the company’s previous close. HC Wainwright also issued estimates for Dyne Therapeutics’ Q1 2025 earnings at ($0.90) EPS, Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.91) EPS and FY2029 earnings at $1.56 EPS.

A number of other brokerages have also weighed in on DYN. Robert W. Baird began coverage on Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Chardan Capital reissued a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research report on Friday, January 10th. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Friday, January 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $48.64.

Dyne Therapeutics Price Performance

DYN opened at $13.61 on Friday. The stock has a 50-day moving average price of $16.98 and a 200-day moving average price of $27.61. The firm has a market cap of $1.39 billion, a PE ratio of -3.82 and a beta of 1.11. Dyne Therapeutics has a 1 year low of $12.87 and a 1 year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. As a group, sell-side analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares in the company, valued at approximately $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Richard William Scalzo sold 1,455 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the transaction, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,387 shares of company stock worth $142,789 in the last three months. 20.77% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. State of New Jersey Common Pension Fund D bought a new position in shares of Dyne Therapeutics during the 3rd quarter valued at approximately $1,588,000. Jennison Associates LLC boosted its stake in Dyne Therapeutics by 1.5% in the 3rd quarter. Jennison Associates LLC now owns 1,346,952 shares of the company’s stock worth $48,383,000 after purchasing an additional 19,730 shares during the period. abrdn plc bought a new position in Dyne Therapeutics in the 4th quarter worth approximately $608,000. RA Capital Management L.P. boosted its stake in Dyne Therapeutics by 5.5% in the 3rd quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after purchasing an additional 331,940 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Dyne Therapeutics by 4.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,859,413 shares of the company’s stock worth $66,802,000 after purchasing an additional 84,760 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.